Role of inflammatory and infectious factors in the development of atherosclerosis


Cite item

Full Text

About the authors

A P Rebrov

I V Voskoboi

References

  1. Климов А. Н., Никульчева Н. Г. Липиды, липопротеиды и атеросклероз. СПб; 1995.
  2. Нагорнев В. А. Атерогенез и иммунное воспаление. Арх. пат. 1995; 57(1): 417-443.
  3. Нагорнев В. А., Кетлинский С. А. Клеточно-молекулярные механизмы становления и развития атерогенеза (CD40СО40Ь-иммунорегуляторный сигнал). Бюл. экспер. биол. 1999; 128(10): 364-371.
  4. Ватутин Н. Т., Чупшш В. А. Инфекция как фактор развития атеросклероза и его осложнений. Кардиология 2000; 40(2): 67-71.
  5. Kleindienst R., Schett G., Amberger A. Atherosclerosis as an autoimmune condition. Israel J. Med. Sci. 1995; 31: 596.
  6. Zhou X., Stemme S., Hansson G. К. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apoli poprotein-E-deficient mice. Am. J. Pathol. 1996; 149: 359-366.
  7. Насонов E. Л., Самсонов М. Ю., Беленков Ю. Н., Фукс Д. Иммунопатология застойной сердечной недостаточности: роль цитокинов. Кардиология 1999; 39(1): 66-73.
  8. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
  9. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999; 340:115-126.
  10. Hansson G. K. Cell-mediated immunity in atherosclerosis. Curr. Opin. Lipidol. 1997; 8: 301-311.
  11. Fuster V., Badimor L., Badimor J., Chesebo J. The pathogenesis of coronary artery disease and acute coronary syndrome. N. Engl. J. Med. 1992; 326: 242-250.
  12. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126-2146.
  13. Libby P. Molecular basic of the acute coronary sybdromes. Ibid. 1995; 91: 2844-2850.
  14. Azar R. R., Waters D. D. The inflammatory etiology of unstable angina. Am. Heart J. 1996; 132: 1101-1106.
  15. Bhakdi S., Dorweiler В., Kirchmann R. et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenetic moiety. J. Exp. Med. 1993; 182: 1959-1971.
  16. Liuzzo G., Biasucci L. M., Gallimore J. R. et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med. 1994; 331: 417-424.
  17. Haverkate F., Thompson S. G., Pyke S. D. M. et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-466.
  18. Ridker P. M., Cushman M., Stampfer M. J. et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently heathy men. N. Engl. J. Med. 1997; 336: 973-979.
  19. Ridker P. M., Buring J. E., Shih J. et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731 - 733.
  20. Ridker P. M., Hennekens С. H., Buring J. E. et al. C-reactive protein and other markers of inflammattion in the prediction of cardiovascular disease in women. N. Engl. J. Med. 2000; 432: 836-843.
  21. Koenig W., Sund M., Frohlich M. et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation 1999; 99: 273-242.
  22. Панченко E. П. Механизмы развития острого коронарного синдрома. Рус. мед. журн. 2000; 8(8): 359-360.
  23. Nityanand S., Bergmark С., de Faire U. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J. Intern. Med. 1995; 238: 437-443.
  24. Wu R., Lefvert A. K. Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL. Clin. Exp. Immunol. 1995; 102: 174-180.
  25. Шичкин В. П. Патогенетическое значение цитокинов и перспективы цитокиновой/антицитокиновой терапии. Иммунология 1998; 2: 9-13.
  26. Симбирцев А. С. Интерлейкин-8 и другие хемокины. Там же 1999; 4: 9-14.
  27. Gregory H., Young J., Schroder J. et al. Structure determination of a human lymphocyte derived neutrophil activating peptide (LYNAP). Biochem. Biophys. Res. Commun. 1988; 151: 883-890.
  28. Schroder J. M., Slicherling M., Henneicke N. H. et al. IL-1 alpha or tumor necrosis factor-alpha stimulate release of three NAP-l/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts. J. Immunol. 1990; 144: 2223-2232.
  29. Cassatella M. A., Bazzoni F., Ceska M. et al. IL-8 production by human polymorphonuclear leukocytes. The chemoattractant formyl-methionyl-leucyl-phenylalanine induces the gene expression and release of IL-8 through a pertusis toxin-sensitive pathway. J. Immunol. 1992; 148: 3216-3220.
  30. Crabtree J. E., Peichl P., Wyatt J. et al. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand. J. Immunol. 1993; 37: 65-70.
  31. Grasing K., Rifici V., Patel M. et al. Interleukin-1 response to arterial antigen, lipopolysaccharide, and oxidized low density lipoprotein in ischemic heart sisease. J. Invest. Med. 1997; 45(8): 474-482.
  32. Schroder J. M., Mrowietz U., Morita E., Christophers E. Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin-1 activity. J. Immunol. 1987; 139: 3474-3483.
  33. Smith D. R., Polverini P. J., Kunkel S. L. et al. Inhibition of interleukin-8 attenuates angiogenesis in bronchogenic carcinoma. J. Exp. Med. 1994; 179: 1409-1415.
  34. Sekido N., Mukaida N., Harada A. et al. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 1993; 365: 654-657.
  35. Hennein H. A., Ebba H., Rodriguez J. L. et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J. Thorac. Cardiovasc. Surg. 1994; 108(4): 626-635.
  36. Hojo Y., Ikeda U., Katsuki T. et al. Interleukin-6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 2000; 84(1): 83-87.
  37. Bayne E. K., Rupp E. A., Limjuco G. et al. Immunocytochemical detection of interleukin-1 within stimulatid human monocytes. J. Exp. Med. 1986; 163: 1267-1280.
  38. Hanson D. F., Murphy P. A. Demonstration of interleukin-1 activity in apparently homogeneous specimens of the pi 5 from of rabbit endogenous pyrogen. Infect, and Immun. 1984; 45: 483-490.
  39. Симбирцев А. С. Биология семейства интерлейкина-1 человека. Иммунология 1998; 3: 9-17.
  40. Cavender D. E., Haskard D. О., Joseph В., Ziff M. Interleukin1 increases the binding of human В and T lymphocytes to endothelial cell monolayers. J. Immunol. 1986; 136: 203-207.
  41. Wade В. Н., Mandell G. L. Polymorphonuclear leukocytes: dedicated professional phagocytes. Am. J. Med. 1983 74: 686-693.
  42. Thomsen M. K. Is interleukin-1 alpha a direct activator of neutrophil migration and phagocytosis in the dog? Agents and Actions 1990; 29: 35-36.
  43. Нестерова И. В., Колесникова Н. В. Цитокиновая регуляция и функционирующая система нейтрофильных гранулоцитов. Гематол. и трансфузиол. 1999; 2: 43-47.
  44. Mason M. J., Van Epps D. E. Modulation of IL-1, tumor necrosis factor, and C5a-mediated murine neutrophil migration by alpha-melanocyte-stimulating hormone. J. Immunol. 1989; 142: 1646-1651.
  45. Яршшн А. А. Система цитокинов и принципы ее функционирования в норме и при патологии. Иммунология 1997; 5: 7-13.
  46. Фрейдлин И. С., Назаров П. Г. Регуляторные функции провоспалительных цитокинов и острофазовых белков. Вестн. РАМН. 1999; 5: 28-32.
  47. Libby P., Ross R. Atherosclerosis and coronary artery disease. Philadelphia; 1996. 585-594.
  48. Kanda Т., Hirao Y., Oschima S. Interleukin-8 as a sensitive marker of unstable coronary artery disease. Am. J. Cardiol 1996; 77: 304-307.
  49. Hasdai D., Scheinowitz M., Leibovitz E. Increased serum concentrations of interleukin-1 p in patient with coronary artery disease. Heart 1996; 76: 24-28.
  50. Мазуров В. И., Столов С. В., Липецкая Н. Э. Динамика уровней провоспалительных цитокинов у больных в зависимости от различных форм ИБС. Клин. мед. 1999; 11: 23-27.
  51. Habib P. M., Springall D. R., Davies G. J. et al. Tumor necrosis factor and inducible nitric oxide syntase in dilated cardiomyopathy. Lancet 1996; 347: 1151 - 1155.
  52. Usui M., Matsuoka H., Miyazaki H. et al. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci. 1998; 62(26): 2425-2430.
  53. Ушакова А. В. Оксид азота и сердечная недостаточность. Доказательная медицина и молекулярная терапия в клинике внутренних болезней. В кн.: Ольбинская Л. И., Маркина С. С. Сборник научных трудов, посвящ. 240-летию ММА им. Сеченова. М.; 1999. 17-29.
  54. Wang D., Yang X. P., Liu Y. H. et al. Reduction of myocardial infarct size by inhibition of inducible nitric oxide synthase. Am. J. Hypertens. 1999; 12: 174-182.
  55. Миролюбива О. А., Добродеева Л. К., Аверина М. Ю. и др. Роль цитокинов и апоптоза в развитии постперфузионного синдрома после операций на открытом сердце с искусственным кровообращением. Кардиология 2001; 41(1): 67-69.
  56. Yue Т. L., Wang С., Romanic A. et al. Stauresporine-induced apoptosis in cardiomyocytes: A potential role for caspace-3. J. Mol. Cell. Cardiol. 1998;30: 494-507.
  57. Cook S.A., Poole-Wilson P. A. Cardiac myocyte apoptosis. Eur. Heart J. 1999; 20: 1619-1629.
  58. Langeler E. G., Fiers W., Hinsberg V. W. M. Effects of tumor necrosis factor on prostacyclin production and the barrier function of human endothelial cell monolayers. Artherioscleros. Thromb. 1991; 11: 872-881.
  59. Barath P., Fischbein M., Cao J. Detection and localisation of tumor necrosis factor in human atheroma. Am. J. Cardiol. 1990; 65: 297-302.
  60. Mann D. L., Young J. B. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 1994; 105: 897-904.
  61. Katz S. D., Rao R., Berman J. et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: relation to nitric oxide-dependent vasodilatation in the forearm circulation. Circulation 1994; 90: 12-16.
  62. Vanderheyden M., Kersschot E., Paulus W. J. Pro-inflammatory cytokines and endothelium-dependent vasodilatation in the foream. Eur Heart J. 1998; 19: 747-752.
  63. Кузник Б. И., Васильев Н. В., Цыбиков Н. Н. Иммуногенез, гемостаз и неспецифическая резистентность организма. М.; 1989.
  64. Gori A. M., Brunelli Т., Рере G. Increased cytokine production in ischaemic heart disease patients. Eur. Heart J. 1998; 19: 506.
  65. Parissis J., Venetsanou K., Ziras N. Abnomal cytokine expression during the cours of acute myocardial infarction. Ibid. 508.
  66. Bickel C., Rupprecht H. J., Blankenberg S. et al. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int. J. Cardiol. 2002; 82(1): 25-31.
  67. Vaddi K., Nicolini F. A., Mehta P. Increased secretion of tumor nesrosis factor-a and interferon-y by mononuclear leukocytes in patients with ischemic heart disease. Relevance in superoxide anion generation. Circulation 1994; 90: 694-699.
  68. Hasdai D., Scheinowitz M., Leibovitz E. Increased serum concentrations of interleiikin-l|3 in patient with coronary artery disiease. Heart 1996; 76: 24-28.
  69. Kanda Т., Hirao Y., Oschima S. Interleukin-8 as a sensitive marker of unstable coronary artery disease. Am. J. Cardiol. 1996; 77: 304-307.
  70. Мазуров В. И., Столов С. В., Липецкая Н. Э. Динамика уровней провоспалительных цитокинов у больных в зависимости от различных форм ИБС. Клин. мед. 1999; 11: 23-27.
  71. Мазуров В. И., Столов С. В., Липецкая Н. Э., Балдуева И. А. Содержание провоспалительных цитокинов интерлейкина-2, интерлейкина-8 и растворимого рецептора интерлейкина-2 в крови у больных ишемической болезнью сердца различных вариантов. Тер. арх. 2001; 12: 14-17.
  72. Братчик А. М., Каменев В. Ф. Фибринолиз, интерлейкины и кардиальный атеросклероз. Клин. мед. 1992; 2: 32- 34.
  73. Vaddi К., Nicolini F. A., Mehta P. Increased secretion of tumor nesrosis factor-a and interferon-y by mononuclear leukocytes in patients with ischemic heart disease. Relevance in superoxide anion generation. Circulation 1994; 90: 694-699.
  74. Hasdai D., Scheinowitz M., Leibovitz E. Increased serum concentrations of interleukin-ip in patient with coronary artery disease. Heart 1996; 76: 24-28.
  75. Сергеева E. Г., Огурцов P. П., Зиновьева Н. А. и др. Туморнекротизирующий фактор и состояние иммунореактивности у больных ишемической болезнью сердца: клиникоиммунологические сопоставления. Кардиология 1999; 39(3): 26-28.
  76. Parissis J., Venetsanou К., Ziras N. Abnomal cytokine expression during the cours of acute myocardial infarction. Eur. Heart. J. 1998; 19: 508.
  77. Bickel C., Rupprecht H. J., Blankenberg S. et al. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int. J. Cardiol. 2002; 82(1): 25-31.
  78. Deswal A., Petersen N. J., Feldman A. M. et al. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarione Trial (VEST). Circulation 2001; 103(16): 2055-2059.
  79. Ikonomidis L., Andreotti F., Economou E. et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Ibid. 1999; 100(8): 793- 798.
  80. Никитин Ю. П., Решетников О. В., Курилович С. А. и др. Ишемическая болезнь сердца, хламидийная и хеликобактерная инфекции (популяционное исследование). Кардиология 2000; 40(8): 4-7.
  81. Ватутин Н. Т., Чупина В. А. Инфекция как фактор развития атеросклероза и его осложнений. Там же (2): 67-71.
  82. Gasbarrini A., Serricchio M., Iondi P. et al. Helicobacter pylori infection and vascular diseases. Ital. J. Gastroenterol. Hepatol. 1998; 30: S307-S309.
  83. Kaukoranta-Tolvanen S. S., Teppo A. M., Laitinen K. et al. Growth of Chlamydia pneumonia in cultured human peripheral blood mononuclear cells and induction of cytokine response. Microb. Pathog. 1996; 21: 215-221.
  84. Kaukoranta-Tolvanen S. S., Ronni Т., Laitinen K. et al. Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. Ibid. 407-411.
  85. Danesh J., Appleby P. Persistent infection and vascular disease: A systemic review. Expert opinion on investig. Drugs 1998; 7: 691-713.
  86. Espinola Klein C., Rupprecht H. I., Blankenberg S. et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002; 105(1): 15-21.
  87. Shor A., Kuo С. С., Patton D. L. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S. Afr. Med. J. 1992; 82: 158-161.
  88. Kuo С. С., Shor A., Campbell L. A. et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J. Infect. Dis. 1993; 167: 841-849.
  89. Melnick S. L., Shahar E., Folsom A. R. et al. Past infection by Chlamydia pneumonia strain TWAR and asymptomatic carotid atherosclerosis. Am. J. Med. 1993; 95: 499-504.
  90. Gupta S., Leatham E. W., Carrington D. et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocarsial infarction. Circulation 1997; 96: 404-407.
  91. Gutfmkel E., Bozovich G., Daroca A. et al. Randomized trial of roxytromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997; 350: 404-407.
  92. Hoffmeister A., Rothenbacher D., Wanner P. et al. Seropositivity to chlamydial lipopolysaccharide and Chlamydia pneumoniae, systemic inflammation and stable coronary disease: negative results of a case-control study. J. Am. Coll. Cardiol. 2000; 35(1): 112-118.
  93. Choussat R, Montalescot G., Collet J. et al. Effect of ptior exposure to Chlamydia pneumoniae, Helicobacter pylori, or cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-Qwave acute myocardial infarction. Am. Cardiol. 2000; 86(4): 379-384.
  94. Визир В. А., Березин А. Е. Иммуновоспалительная активация как концептуальная модель формирования и прогрессирования сердечной недостаточности. Тер. арх. 2000; 4: 77-80.
  95. Насонов Е. А. Маркеры воспаления и атеросклероз: значение С-реактивного белка. Кардиология 1999; 39(2): 81 - 85.
  96. Ольбинская Л. И., Игнатенко С. Б. Роль системы цитокинов в патогенезе хронической сердечной недостаточности. Тер. арх. 2001; 12: 82-84.

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies